WO2000045162A1 - Agents empechant la coagulation sanguine et recipients de collecte de sang les contenant - Google Patents

Agents empechant la coagulation sanguine et recipients de collecte de sang les contenant Download PDF

Info

Publication number
WO2000045162A1
WO2000045162A1 PCT/JP1999/007159 JP9907159W WO0045162A1 WO 2000045162 A1 WO2000045162 A1 WO 2000045162A1 JP 9907159 W JP9907159 W JP 9907159W WO 0045162 A1 WO0045162 A1 WO 0045162A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
magnesium
blood collection
coagulation
test
Prior art date
Application number
PCT/JP1999/007159
Other languages
English (en)
Japanese (ja)
Inventor
Noriyuki Tatsumi
Original Assignee
Nagase & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagase & Co., Ltd. filed Critical Nagase & Co., Ltd.
Priority to AU16904/00A priority Critical patent/AU1690400A/en
Publication of WO2000045162A1 publication Critical patent/WO2000045162A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se

Definitions

  • the present invention relates to a novel anticoagulant and a blood collection container containing the same. More specifically, the present invention relates to a blood coagulation inhibitor which effectively prevents blood coagulation, and is particularly preferably used to prevent blood coagulation collected for a blood test used for various diagnoses, and The present invention relates to a blood collection container in which is stored. Background art
  • test physiological test
  • Biological components such as blood, urine, and tissues.
  • This blood test includes (1) chemical tests to check electrolytes and pH, (2) measurement of chemical components in blood, measurement of infectious diseases, blood types, cancer-related antigens, etc. Furthermore, they can be broadly divided into biochemical tests for examining bacteria, viruses and pathological cells, and (3) blood tests for examining the morphology and number of blood cells and coagulation function.
  • the blood of the subject is collected in a blood test container, and in this case, measures are taken so that the collected blood does not coagulate before being subjected to the test. It is important.
  • Blood is fluid while circulating in blood vessels, but once removed outside the blood vessels, it loses fluidity, for example, once it is transferred into a test tube. This is because fibrinogen in plasma is converted into fibrin fibrin, forming a fibrin web, This is because the whole liquid becomes a gel and solidifies.
  • Such coagulation is initiated when blood coagulation factor XII in plasma comes into contact with a surface (eg, glass) of a negatively charged solid phase or the like. That is,
  • Factor XII would when adsorbed on the surface activated factor XII (XII a), which is interposed calcium ions, acts on each coagulation factor, ultimately to produce a thrombin, the thrombin Fuiburino one Gen Limited digestion to fipurin, and fibrin is converted to blood coagulation factor XIII (XI
  • Various types of blood have been developed and used to prevent such coagulation of collected blood.
  • metal salts of ethylenediaminetetraacetic acid, sodium citrate, sodium heparin, synthetic hirudin, and a sulfonated gen-based polymer having a weight-average molecular weight of 300 or more or a salt thereof JP-A-8-43337) No. 7 is known as a blood coagulation inhibitor for blood collection.
  • the present invention can be applied to blood tests of all chemical, biochemical and blood items, is versatile, has an excellent effect of preventing blood coagulation, and
  • An object of the present invention is to provide a blood coagulation inhibitor which is stable in effect and is inexpensive, and a blood collection container containing the same. Disclosure of the invention
  • the present inventor has conducted intensive studies to develop a blood coagulation inhibitor having the above preferred properties and a blood collection container containing the same, and as a result, the inorganic acid salt of magnesium has an unexpectedly excellent blood coagulation prevention effect,
  • the present inventors have found that the agent can be used as a universal anticoagulant, and based on this finding, have completed the present invention.
  • the present invention (1) an anticoagulant comprising an inorganic salt of magnesium as an active ingredient,
  • a blood collection container containing a magnesium salt of inorganic acid in the container containing a magnesium salt of inorganic acid in the container
  • the anticoagulant of the present invention contains magnesium as an active ingredient and is particularly effective in preventing coagulation of blood collected for a blood test.
  • Magnesium sulfate and its hydrous salts are particularly preferred in terms of performance and cost.
  • thrombin has a function of converting fibrinogen into fibrin by limited degradation and fibrin network formation by fibrin crosslinking. It is presumed that calcium ions in the blood involved are replaced by magnesium ions.
  • the blood coagulation inhibitor of the present invention together with the inorganic acid salt of magnesium, as far as the object of the invention is not impaired, conventionally known substances having an anticoagulant action, for example, metal salts of ethylenediamine tetrafate, sodium citrate, sodium heparin, synthetic hirudin, sulfonated gen-based polymers, if desired Alternatively, a salt thereof, or another thrombin inhibitor or the like can be appropriately used.
  • thrombin inhibitors include, for example, gabexate methylate, nafamostat mesylate, (2R, 4R) —4-methyl-1- 1— [N 2 — (3-methyl-1,2,3, 4-tetrahydro-18-quinolinesulfonyl) -1-L-arginyl] -12-piperidinecarboxylic acid monohydrate.
  • the amount of the blood coagulation inhibitor of the present invention added to blood is appropriately selected depending on the type of the inorganic acid salt of magnesium and the desired anticoagulation time, but is usually 1 to 50 ragZml, preferably 2 to 4 Omg. / ml range. If the added amount is less than 1 mgZml, the effect of preventing blood coagulation may not be sufficiently exerted, and if it exceeds 5 OmgZinl, the effect is not improved for the amount, but rather adversely affects the blood test. May be given.
  • the form of the anticoagulant of the present invention is not particularly limited, and may be in the form of a powder, an aqueous solution or an aqueous suspension contained in an aqueous medium.
  • an aqueous medium that does not disturb the blood test preferably, physiological saline can be used.
  • the blood collection container of the present invention contains the inorganic salt of magnesium in a container, and the inorganic salt of magnesium is used as a powder, an aqueous solution or an aqueous suspension.
  • the inorganic acid salt of magnesium may be used alone or in combination of two or more.
  • magnesium sulfate and its hydrated salt are particularly preferable. Further, as long as the object of the present invention is not impaired, a conventionally known substance having an anticoagulant effect as described above may be appropriately used in combination.
  • the blood collection container of the present invention means a container such as a blood collection tube, a blood collection bottle, a blood collection bag, or the like for collecting or storing blood for a blood test, for whole blood, for separating serum, for analyzing sugar, and the like.
  • a vacuum blood collection tube is most suitable as the container. is there.
  • This vacuum blood collection tube is usually put into practical use as a vacuum blood collection system combined with accessory devices such as a holder and a blood collection needle.
  • a resin such as a thermoplastic resin, a thermosetting resin or a modified natural resin, or glass can be used.
  • thermoplastic resin examples include polyethylene, polypropylene, poly-4-methylpentene-11, polystyrene, polymethyl methacrylate, polyvinyl chloride, polyethylene terephthalate, polybutylene terephthalate, styrene-acrylonitrile copolymer, and styrene.
  • thermosetting resins such as unsaturated polyester resins, epoxy resins, and epoxy resins. Kishi acrylate resins, and examples of the modified natural resins, cellulose acetate, propyl propionic acid, cellulose acetate butyrate, E chill cellulose, Echirukichin like are used.
  • a silicate glass such as a soda-lime glass, a phosphoric acid glass, a borate glass, or a quartz glass is preferably used.
  • the capacity of the blood collection container is appropriately selected depending on the purpose of use of the container, but is usually in the range of 2 to 2 nil.
  • the amount of inorganic salt of magnesium housed in the blood collection container, per blood l ml for preparative adopted usually 3 to 5 O mg, preferably 3. 1 5 ⁇ 3 1. 5 mg c
  • the blood collection container of the present invention may be of a vacuum type in which a cap made of, for example, butyl rubber is provided and the inside is evacuated, or may be of a non-vacuum type. Types are preferred. Further, before or after storing the inorganic acid salt of magnesium, the magnesium salt can be sterilized if necessary.
  • Magnesium nitrate as well as comparative experiment [Mg (N0 3) 2 ' 6H 2 0, Wako Pure Chemical Industries, Ltd.], zinc sulfate [ZnS0 4 * 7H 2 0, USA Sigma] was measured time of blood coagulation by .
  • the anticoagulant of the present invention can be applied to blood tests of all chemical, biochemical and blood items, is versatile, has an excellent effect of preventing blood coagulation, and its effect is stable. Moreover, it is inexpensive and has high practical value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des agents empêchant la coagulation sanguine, contenant, en tant que principe actif, un sel d'acide inorganique de magnésium ; des récipients de collecte de sang contenant un sel d'acide inorganique de magnésium. Etant donné qu'ils sont capables d'empêcher efficacement la coagulation sanguine, ces agents et récipients sont utilisables efficacement, notamment pour empêcher la coagulation d'échantillons sanguins prélevés pour divers examens diagnostiques.
PCT/JP1999/007159 1999-01-26 1999-12-20 Agents empechant la coagulation sanguine et recipients de collecte de sang les contenant WO2000045162A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16904/00A AU1690400A (en) 1999-01-26 1999-12-20 Blood coagulation preventing agents and blood collection containers containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11/17624 1999-01-26
JP11017624A JP2000210380A (ja) 1999-01-26 1999-01-26 血液凝固阻止剤及びそれを収納した採血容器

Publications (1)

Publication Number Publication Date
WO2000045162A1 true WO2000045162A1 (fr) 2000-08-03

Family

ID=11949033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/007159 WO2000045162A1 (fr) 1999-01-26 1999-12-20 Agents empechant la coagulation sanguine et recipients de collecte de sang les contenant

Country Status (3)

Country Link
JP (1) JP2000210380A (fr)
AU (1) AU1690400A (fr)
WO (1) WO2000045162A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692772B2 (en) 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4592422B2 (ja) * 2002-11-18 2010-12-01 デンカ生研株式会社 血清および血漿の測定値乖離を防止する免疫測定法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63181861U (fr) * 1987-05-11 1988-11-24
JPH05131026A (ja) * 1990-10-09 1993-05-28 Marquest Medical Prod Inc 注射器内での血液の凝固を防止する方法および綿撒糸
JPH08271508A (ja) * 1995-03-28 1996-10-18 Sekisui Chem Co Ltd 血液検査用容器及び担体
JPH08275932A (ja) * 1994-08-23 1996-10-22 Becton Dickinson & Co 採血装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63181861U (fr) * 1987-05-11 1988-11-24
JPH05131026A (ja) * 1990-10-09 1993-05-28 Marquest Medical Prod Inc 注射器内での血液の凝固を防止する方法および綿撒糸
JPH08275932A (ja) * 1994-08-23 1996-10-22 Becton Dickinson & Co 採血装置
JPH08271508A (ja) * 1995-03-28 1996-10-18 Sekisui Chem Co Ltd 血液検査用容器及び担体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692772B2 (en) 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
US7452373B2 (en) 2001-07-18 2008-11-18 Cedars-Sinai Medical Center Stent coated with magnesium-based compound for reducing thrombosis

Also Published As

Publication number Publication date
AU1690400A (en) 2000-08-18
JP2000210380A (ja) 2000-08-02

Similar Documents

Publication Publication Date Title
EP0730154B1 (fr) Recipient et support pour examens sanguins comprenant un inhibiteur d'adherence des facteurs sanguins
RU2006139643A (ru) Способ сбора, хранения и транспортировки биологических образцов и устройство для его осуществления
WO2005116641A1 (fr) Outil de collecte d'échantillon biologique et méthode de collecte d'échantillon biologique
JPH04241873A (ja) ヘパリンを除去する方法及び装置
JP2866803B2 (ja) 採血管用二経路凝血促進剤
WO2000045162A1 (fr) Agents empechant la coagulation sanguine et recipients de collecte de sang les contenant
JP3495106B2 (ja) 血液成分付着防止剤、血液検査用容器および血液成分付着防止性担体
Tew et al. Release of β-lysin from platelets by thrombin and by a factor produced in heparinized blood
JP3420855B2 (ja) 血液検査用容器及び担体
US5593639A (en) Blood-sampling vessel
JP2001527530A (ja) 血液、血漿または関節液生成物の抗凝血
JPH06769Y2 (ja) 採血管
JP2000292421A (ja) 血液処理方法及び採血管
JPS58158556A (ja) 血液検査用容器
Denizli et al. Competitive adsorption of blood proteins on gamma-irradiated-polycarbonate films
JP3478903B2 (ja) 血液凝固促進剤
JPS58143267A (ja) 血液検査用容器
Page et al. Platelet adhesiveness to glass
JPH11318865A (ja) 採血管
JPH0155416B2 (fr)
JP3420856B2 (ja) 血液凝固促進剤の製造方法
JP2001124766A (ja) 血液検査用具
JP3543420B2 (ja) 採血容器
JP2005006821A (ja) 血液を血漿層／血球層に分離するための採血器具および方法
JPH1172493A (ja) 血液検査用容器及び血液抗凝固方法

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16904

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN ID IN KR SG US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase